Clinical trial NCT06073171: Genomic Study of Cutis Tricolor
Official title: Genomic Study of Cutis Tricolor
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Pigmentary; Dermatosis
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
Collaborators: name: IntegraGen SA
First posted: 2023-10-10
Enrollment: 10
Sex: ALL
Minimum age (years): 4
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: It's a study on Syndromic or Isolated Cutis Tricolor and had as main goal to identify the associated gene to the disease thanks to genetic analysis on minors patients and their parents reach by cutis Tricolor or not.

Detailed description: Cutis Tricolor (CT) is a rare cutaneous anomaly defined by pigmentary disorders associating large hyper- and hypopigmented macules of immediate proximity, selectively affecting the trunk. CT can be isolated, sporadic or integrated as a complex syndromic form such as Ruggieri-Happle syndrome (RHS) or various forms of pigmentovascular phacomatosis. A recent analysis of one case of RHS followed by CHU of Montpellier by whole exome sequencing allows the identification of a frameshift pathogen variant (heterozygous state) of a candidate gene.

The main objective is to confirm the association of the candidate gene with syndromic CT (SCT, Ruggierri-Happle syndrome) and non syndromic CT, from a genetic molecular blood and biopsy analysis of patients reach by CT and their parents presenting the disease or not. Furthermore, other objectives are to identify others associated candidates genes and to know better cutaneous pigmentary troubles factors, neurologics and eye abnormalities by identifying the differents cellulars pathways particularly the inflammatory pathway in the pathology of SCT.

First of all, it will have a pre-inclusion visit where Dr WILLEMS. M (Clinical Genetic Department - CHU Montpellier, France) and Pr BESSIS. D (Dermatology Department - CHU Montpellier, France) will explain the study's progress. Then, during the inclusion visit, families will sign inform consent for inclusion in the study. The same day, datas will be collected on demographic, clinical datas, including (i) a description of cutaneous, morphologic and extra-cutaneous anomalies and (ii) a cutaneous biopsy and (iii) a blood test will be done.

The genetics exams results will be return to patients during an usual follow-up visit, 12 months after their inclusion in the study.

Eligibility criteria: Inclusion Criteria:

* Patients with Cutis Tricolor in trio (an affected parent, an unaffected parent) or in duo (one of the two affected parents)
* Age : from 4 to 60 years

Exclusion Criteria:

* Refusal to sign the informed consent
* Patient who doesn't have a social security scheme or beneficiary of such a scheme
* Pregnant or breastfeeding women
* Patient whith a legal protection measure (guardianship, curatorship)
* Patient under legal protection

Primary outcomes:
measure: Number of patients in whom a pathogenic or probably pathogenic variant has been identified by exome sequencing
timeFrame: 12 months
Secondary outcomes:
measure: Number of patients in whom a pathogenic or probably pathogenic variant in the same gene as another patient in the series has been identified
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
References: